Al-Jamal, Hamid Ali Nagi <br/><br/>
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.  [electronic resource] 

 -  BMC cancer  Nov 2015 
 - 869 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-015-1695-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Azacitidine--pharmacology<br/>Carbazoles--pharmacology<br/>Cell Line, Tumor<br/>Cells, Cultured<br/>DNA Methylation<br/>Drug Resistance, Neoplasm--genetics<br/>Furans<br/>Gene Duplication<br/>Gene Expression Regulation, Leukemic--drug effects<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Protein Tyrosine Phosphatase, Non-Receptor Type 6--genetics<br/>STAT3 Transcription Factor--metabolism<br/>fms-Like Tyrosine Kinase 3--genetics